Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904683 · ClinicalTrials.gov registry record · Phase 3
Effect of LY2062430 on the Progression of Alzheimer's Disease
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,040
- Enrollment target
NCT00904683 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,040 participants.
The verdict
NCT00904683, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,040 participants
- Enrollment target
Study Summary
Alzheimer's disease (AD) is an age-related degenerative disorder of the brain, characterized by progressive decline in cognitive function and ability to perform activities of daily living, and ultimately can lead to death due to complications of the disease. AD is thought to be caused by an excess of A-Beta amyloid, a sticky protein in the brain that forms amyloid plaques. Treatments that slow the synthesis or deposition of A-Beta amyloid, or that increase clearance, might be expected to slow the progression of AD. LY2062430 (solanezumab) is a humanized anti-A Beta peptide immunoglobulin G-1 (IgG1) monoclonal antibody being developed for the treatment of AD. The primary hypothesis being tested is that LY2062430 will slow cognitive and functional decline in AD as compared with placebo. Each patient's participation will last approximately 19 months. Patients taking approved AD medications may participate in this study and continue taking these medications during the study.
Interventions
- DRUG Placebo
- DRUG LY2062430
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,040 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00904683
The ClinicalTrials.gov registry entry for NCT00904683 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,040 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00904683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00904683 about?
NCT00904683 is a clinical study titled "Effect of LY2062430 on the Progression of Alzheimer's Disease". Alzheimer's disease (AD) is an age-related degenerative disorder of the brain, characterized by progressive decline in cognitive function and ability to perform activities of daily living, and ultimately can lead to death due to complications of the disease. AD is thought to be caused by an excess o...
What is the current status of trial NCT00904683?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,040 participants. The study started on 2009-05. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00904683?
The interventions under investigation include: Placebo (DRUG), LY2062430 (DRUG).
Who is sponsoring clinical trial NCT00904683?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.